絞り込み

16645

広告

Rituximab immunotherapy for ocular adnexal lymphoma: clinicopathologic correlation with 5-year follow-up.

著者 Sokol JA , Landau L , Lauer SA
Ophthal Plast Reconstr Surg.2009 Jul-Aug ; 25(4):322-4.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Departments of Ophthalmology and Visual Sciences, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, New York, USA. jsokolmd@gmail.com

スターを付ける スターを付ける     (21view , 0users)

Full Text Sources

Medical

Miscellaneous

Two patients with primary ocular adnexal mucosa-associated lymphoid tumor lymphoma were treated with rituximab immunotherapy. One patient had refused radiotherapy. The other had bilateral ischemic retinopathy, a relative contraindication to radiotherapy. Biopsies were performed 6 months after treatment. One patient had complete resolution of local disease, and the other had a partial response, remaining stable without signs of progression. During the 5 years of clinical follow-up, there was no evidence of systemic disease in either patient. Rituximab immunotherapy is an alternative to regional radiotherapy for ocular adnexal mucosa-associated lymphoid tumor lymphoma.
PMID: 19617799 [PubMed - indexed for MEDLINE]
印刷用ページを開く Endnote用テキストダウンロード